Momenta Phama (MNTA) Announces Proposed $200M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 10, 2019 4:04 PM ESTCAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common stock. Momenta also expects to grant the underwriters of the offering an option to purchase up to an additional $30,000,000 of shares of its common stock, exercisable for 30 days. All of the shares in the proposed offering are to be sold by Momenta.
Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering. Stifel is acting as a... More
